ALDX Investor Alert: Aldeyra Therapeutics Securities Fraud Lawsuit – Investors With Losses May Seek to Lead the Class Action After Company Allegedly Omitted Inconsistent Trial Data: Levi & Korsinsky

Key Takeaways:

• Aldeyra allegedly omitted inconsistent reproxalap trial data.
• The relevant period for shareholders spans November 3, 2023 to March 16, 2026.
• Aldeyra’s share price plunged 70.7%, fueling the lawsuit.
• The FDA’s March 2026 letter flagged unreliable trial conclusions.
• The lead plaintiff deadline is May 29, 2026.

A Securities Fraud Claim Emerges

Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) has found itself at the center of a major legal controversy. A class action lawsuit, filed by Levi & Korsinsky, LLP, accuses the company of withholding or disregarding critical clinical trial data for its investigational therapy, reproxalap. According to the complaint, senior officers repeatedly touted positive findings throughout a multi-year period, despite allegedly inconsistent results.

Alleged Omissions Behind the Lawsuit

Court documents suggest that company leaders either knew or recklessly ignored that reproxalap’s clinical outcomes were not as robust as publicly stated. From November 2023 to March 2026, Aldeyra’s SEC filings described reproxalap as demonstrating “rapid-onset activity and consistent safety.” The lawsuit claims this messaging lacked a sound basis, given the underlying data that the FDA later found problematic.

FDA Cites Inconsistencies

In March 2026, the FDA issued a Complete Response Letter that pointed to inconsistencies across multiple reproxalap trials. While no single event caused the failure, the regulatory agency determined that positive findings were “unreliable and not meaningful.” These conclusions cast doubt on the accuracy of Aldeyra’s previous claims and quickly escalated investor concerns.

Stock Price Collapse

On the heels of the FDA’s letter, Aldeyra’s shares plunged by 70.7%, representing a loss of $2.99 per share. This dramatic sell-off not only underscored the severity of the situation but also prompted a wave of shareholder dissatisfaction. Many investors, who relied on Aldeyra’s upbeat statements, now seek answers through legal channels.

Seeking Lead Plaintiffs

Levi & Korsinsky, LLP, which is spearheading the lawsuit, urges investors who purchased Aldeyra stock between November 3, 2023, and March 16, 2026, to consider joining the class action. The lead plaintiff filing deadline is May 29, 2026. This legal process aims to recover possible financial losses incurred by shareholders who relied on the company’s optimistic public communications.

Next Steps in the Legal Battle

As of now, Aldeyra has not publicly addressed the specific allegations beyond what is outlined in regulatory filings. The lawsuit’s progression will likely hinge on further examination of clinical data and the accuracy of the company’s public statements. For investors, the coming months will provide greater clarity on both the drug’s future and any potential financial redress.